Skip to content

Company
Pipeline
For Investors
Contact

Company
Pipeline
For Investors
Contact

Press Releases

Choose Year
Search Press Releases

Found 267 Results

September 9, 2015

Relmada Therapeutics Announces Issuance of U.S. Patent Covering SECUREL™ – an Abuse-Deterrent, Extended-Release, Technology Platform for Opioids

September 2, 2015

Relmada Therapeutics to Participate in Two Upcoming Investor Conferences

August 17, 2015

Relmada Therapeutics Receives Health Canada Clearance to Commence Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist

August 12, 2015

Relmada Therapeutics Announces Launch of New Website and Corporate Communication Channels

August 10, 2015

Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market

July 27, 2015

Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone

July 16, 2015

Relmada Therapeutics Appoints Charles J. Casamento to Its Board of Directors

June 29, 2015

Enrollment in Relmada Therapeutics’ Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark

June 15, 2015

Relmada Therapeutics to Present at 2015 BIO International Convention

June 10, 2015

Relmada Therapeutics Successfully Completes Phase 1 Single Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone

«...21 222324 25 26...»

IR Contact

Brian Ritchie
LifeSci Advisors, LLC

+1 (212) 915-2578
britchie@lifesciadvisors.com

Email Alerts Sign-Up

Email

I accept the Privacy Policy^*

Unsubscribe

Loading...

Company

Pipeline
Overview
NDV-01
Speranolone

For Investors
Summary
News
Events
SEC Filings
Corporate Governance
Stock Information

Contact

info@relmada.com

+1 (786) 629-1376

©2026 Relmada Therapeutics, Inc.

Privacy Policy
Terms of Use

Scroll to Top